Weight loss was significant in outcome trials, ranging from a 0.6 kg reduction at 12 weeks in the ELIXA trial to a 4.3 kg reduction at 2 years with injectable semaglutide in the SUSTAIN-6 trial
Recent studies have highlighted the role of inflammation, oxidative stress, and hypoxia as key mediators that link OSAS with various comorbidities, such as cardiovascular disease, diabetes, and neurocognitive disorders [7,8]
Based on current evidence, GLP-1RAs are not recommended as first-line therapy for type 2 diabetic patients at high risk for colorectal cancer [47]
When should I seek medical help for headaches whilst taking weight loss injections
collision energy) of metabolites were as follows
Ibrahim RB, Yeh SY, Lin KP, Ricardo F, Yu TY, Chan CC, Tsai JW, Liu YT